Disclosures 2011
Pursuant to article 26a WpHG, BB Biotech AG, Vordergasse 3, 8200 Schaffhausen, Switzerland, hereby announces that the total voting rights at the end of March 2012 amounted to 14 762 250.
The new number of voting rights is effective as of March 1, 2012.
Pursuant to article 20 BEHG BB Biotech AG, Vordergasse 3, 8200 Schaffhausen and its wholly-owned subsidiary Biotech Target N.V., Snipweg 26, Curaçao, hereby report that their voting rights were increased to above 20% of the proportion of voting rights of BB Biotech AG as at March 1, 2012, due to the purchase of shares.
Pursuant to article 20 BEHG BB Biotech AG, Vordergasse 3, 8200 Schaffhausen and its wholly-owned subsidiary Biotech Target N.V., Snipweg 26, Curaçao, hereby report that their voting rights were reduced to below 20% of the proportion of voting rights of BB Biotech AG as at March 1, 2012, due to the capital reduction.
Pursuant to article 20 BEHG BB Biotech AG, Vordergasse 3, 8200 Schaffhausen and its wholly-owned subsidiary Biotech Target N.V., Snipweg 26, Curaçao, hereby report that they increased their voting rights to more than 25% of the proportion of voting rights of BB Biotech AG as at February 20, 2012.
Pursuant to article 20 BEHG BB Biotech AG, Vordergasse 3, 8200 Schaffhausen and its wholly-owned subsidiary Biotech Target N.V., Snipweg 26, Curaçao, hereby report that they increased their voting rights to more than 20% of the proportion of voting rights of BB Biotech AG as at November 14, 2011.
Pursuant to article 20 BEHG BB Biotech AG, Vordergasse 3, 8200 Schaffhausen and its wholly-owned subsidiary Biotech Target N.V., Snipweg 26, Curaçao, hereby report that they increased their voting rights to more than 15% of the proportion of voting rights of BB Biotech AG as at July 29, 2011.
Pursuant to article 20 BEHG BB Biotech AG, Vordergasse 3, 8200 Schaffhausen and its wholly-owned subsidiary Biotech Target N.V., Snipweg 26, Curaçao, hereby report that their voting rights were reduced to below 15% of the proportion of voting rights of BB Biotech AG as at July 25, 2011, due to the capital reduction.
Pursuant to Art. 9 and Art. 21 SESTO-FINMA, The Bank of New York Mellon Corporation, New York, USA, has announced to BB Biotech AG, Schaffhausen, Switzerland, that its holding in registered shares BB Biotech AG (ISIN CH0038389992) increased to more than 5% of the proportion of voting rights as per May 27, 2011.
Pursuant to Art. 9 and Art. 21 SESTO-FINMA, The Bank of New York Mellon Corporation, New York, USA, has announced to BB Biotech AG, Schaffhausen, Switzerland, that its holding in registered shares BB Biotech AG (ISIN CH0038389992) increased to more than 3% of the proportion of voting rights as per May 12, 2011.
Pursuant to article 20 BEHG BB Biotech AG, Vordergasse 3, 8200 Schaffhausen and its wholly-owned subsidiary Biotech Target N.V., Snipweg 26, Curaçao, hereby report that they increased their voting rights to more than 20% of the proportion of voting rights of BB Biotech AG as at March 8, 2011.
